For sales

📢Highlights from the Week of May 19–23, 2025 in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of May 19–23, 2025 ( Global Licensing ) Pfizer entered into an exclusive global licensing agreement with China's 3SBio for the development, manufacturing and commercialization of SSGJ-707; 3SBio anticipates a Ph3 study in China in 2025 ( FDA ) The FDA's ODAC voted in favor of J&J's DARZALEX FASPRO for high-risk smoldering multiple myeloma (HR-SMM); based on results from the Ph3 AQUILA study ( Partnership ) Northway Biotech partnered with Kaida BioPharma to manufacture KAD101 for hormone-driven cancers, such as ovarian cancer; the Ph1 trial is expected to start in Q4 2026 or Q1 2027 ( Collaboration ) Mirai Bio partnered with Thermo Fisher for the development and manufacturing of its genetic medicines; Fisher to serve as a CDMO for cGMP services and commercial manufacturing Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.